Dermata Therapeutics
DRMA
8 hedge funds and large institutions have $236K invested in Dermata Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
398% more capital invested
Capital invested by funds: $47.4K → $236K (+$189K)
100% more funds holding
Funds holding: 4 → 8 (+4)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$102K |
| 2 |
VF
Virtu Financial
New York
|
+$58.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.9K |
| 5 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$34K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.36K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$273 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $92K | +$102K | +375 | New |
|
|
VF
2
Virtu Financial
New York
| $53K | +$58.4K | +214 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $28.5K | +$31.4K | +115 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20.9K | +$22.9K | +84 | New |
|
|
HWA
5
HCR Wealth Advisors
Los Angeles,
California
| $19.8K | +$21.8K | +80 | New |
|
6
UBS Group
Zurich,
Switzerland
| $11.6K | +$6.55K | +24 | +104% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $9.38K | -$273 | -1 | -3% |
|
|
8
Wells Fargo
San Francisco,
California
| $1.16K | -$1.36K | -5 | -50% |
|
|
9
Renaissance Technologies
New York
| – | -$34K | -176 | Closed |
|
DRMA Hedge Fund Activity: Q2 2023 in Review
8 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q2 2023, worth a combined $236K — up 398% from $47.4K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DRMA positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $102K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $34K sold.
- 8 institutional investors held Dermata Therapeutics (DRMA) as of Q2 2023, up from 4 in Q1 2023.
- Funds reported $236K of Dermata Therapeutics stock for Q2 2023, up 398% quarter-over-quarter.
- 5 funds opened new Dermata Therapeutics positions in Q2 2023 and 1 closed out, a net change of +4 holders.
- The largest Dermata Therapeutics buyer in Q2 2023 was Acadian Asset Management, an estimated $102K added.
- The largest Dermata Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $34K sold.
Based on aggregated 13F filings for Q2 2023.